MedTech Dive May 16, 2025
In earnings calls, diabetes tech companies had less to say about tariffs and focused more on future growth.
Dexcom CEO Kevin Sayer touted the company’s recent efforts to expand coverage of CGMs for people with Type 2 diabetes. On a May 1 earnings call, the CEO told investors that all three major U.S. pharmacy benefit managers now cover the company’s G7 glucose monitor for anyone with diabetes. Dexcom expects to have coverage for nearly 6 million people with Type 2 diabetes who don’t take insulin by the end of the year.
“While this still represents only a portion of this 25 million-person population in the U.S., we often see smaller and customized plans quickly follow suit of the larger...
Today's Sponsors
Today's Sponsor